Literature DB >> 10969688

Amrinone preconditioning in the isolated perfused rabbit heart.

A E Saltman1, G R Gaudette, S Levitsky, I B Krukenkamp.   

Abstract

BACKGROUND: Ischemic preconditioning (IPC) reduces infarct size in experimental preparations. IPC, however, is not without detrimental effects. We studied amrinone as a possible alternative to IPC.
METHODS: Isolated perfused rabbit hearts were given a 5-minute infusion of 10 micromol/L amrinone followed by a 5-minute washout (n = 6). The anterior descending artery was then occluded for 1 hour and reperfused for 1 hour. Six hearts underwent IPC, with two episodes of 5-minute global ischemia followed by 5-minute reperfusion before LAD occlusion; eight control hearts received no preconditioning. Left ventricular pressure and ischemic zone epicardial monophasic action potentials were continuously monitored.
RESULTS: IPC but not amrinone reduced peak pressure before anterior descending artery occlusion. Peak pressure fell significantly during ischemia and reperfusion in all hearts. End diastolic pressure rose significantly during reperfusion in control and IPC hearts but not in amrinone hearts. Action potentials shortened during ischemia in all hearts. They returned to preocclusion values in control hearts but lasted beyond preocclusion values in IPC and amrinone hearts. Both the incidences of ventricular fibrillation and infarct size were significantly reduced in amrinone hearts but not in IPC hearts.
CONCLUSIONS: Amrinone is not only a useful inotropic agent but is also a superior preconditioning agent when compared to IPC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969688     DOI: 10.1016/s0003-4975(00)01554-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion.

Authors:  Shinya Tosaka; Tetsuji Makita; Reiko Tosaka; Takuji Maekawa; Sungsam Cho; Tetsuya Hara; Hiroyuki Ureshino; Koji Sumikawa
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

2.  Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.

Authors:  Yukiya Nomura; Hitoshi Horimoto; Shigetoshi Mieno; Ken-ichi Nakahara; Hirohisa Okawa; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

3.  Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury.

Authors:  Masayoshi Oikawa; Meiping Wu; Soyeon Lim; Walter E Knight; Clint L Miller; Yujun Cai; Yan Lu; Burns C Blaxall; Yasuchika Takeishi; Jun-ichi Abe; Chen Yan
Journal:  J Mol Cell Cardiol       Date:  2013-08-27       Impact factor: 5.000

Review 4.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.